Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2017). Efficacy and Safety of Once-Weekly Semaglutide versus Exenatide ER in subjects with Type 2 Diabetes (SUSTAIN 3): a 56-Week, Open-Label, randomized clinical trial. Diabetes Care , 41 (2), 258–266. https://doi.org/10.2337/dc17-0417 Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019). Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. The Lancet. Diabetes & Endocrinology , 7 (10), 776–785. https://doi.org/10.1016/s2213-8587(19)30249-9 Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017). Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity & Metabolism/Diabetes, Obesity and Metabolism , 19 (9), 1242–1251. https://doi.org/10.1111/dom.12932 Urva, S., O’Farrell, L., Du, Y., Loh, M. T., Hemmingway, A., Qu, H., Alsina‐Fernandez, J., Haupt, A., Milicevic, Z., & Coskun, T. (2023b). The novel GIP, GLP‐1 and glucagon receptor agonist retatrutide delays gastric emptying. Diabetes, Obesity & Metabolism/Diabetes, Obesity and Metabolism , 25 (9), 2784–2788. https://doi.org/10.1111/dom.15167

Information for GLP-1-S

GLP-1-S is a glucagon-like peptide-1 (GLP-1) receptor agonist that has demonstrated significant effects on body weight and cardiometabolic endpoints in experimental research settings. In controlled trials, once-weekly administration of 2.4 mg GLP-1-S led to consistent weight reductions of up to 16.0% and was associated with decreased incidence of cardiovascular events over long-term observation (Garvey et al., 2022; Bergmann et al., 2023; Lincoff et al., 2023; Marso et al., 2016).

References

Bergmann, N. C., Davies, M. J., Lingvay, I., & Knop, F. K. (2023). Semaglutide for the treatment of overweight and obesity: A review. Diabetes, Obesity and Metabolism, 25(1), 18–35. https://doi.org/10.1111/dom.14863

Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., ... & Wharton, S. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28, 2083–2091. https://doi.org/10.1038/s41591-022-02026-4

Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., ... & Ryan, D. H. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 389(24), 2221–2232.
https://doi.org/10.1056/NEJMoa2307563

Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New
England Journal of Medicine, 384(11), 989–1002.
https://doi.org/10.1056/NEJMoa2032183

Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., ... & Vilsbøll, T. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 375(19), 1834–1844.
https://doi.org/10.1056/NEJMoa1607141

Order GLP-1-S 5mg

Order GLP-1-S 10mg

Order GMP GLP-1-S 5mg

Order GMP GLP-1-S 10mg

GMP Certificates of Analysis

GLP-1-S<br>6.40mg<br>Batch V260127-3 007<br>02/16/2026

GLP-1-S
6.40mg
Batch V260127-3 007
02/16/2026

GLP-1-S<br>5.75mg<br>Batch V260127-3 008<br>02/16/2026

GLP-1-S
5.75mg
Batch V260127-3 008
02/16/2026

GLP-1-S<br>5.67mg<br>Batch V250915-17 004<br>10/02/2025

GLP-1-S
5.67mg
Batch V250915-17 004
10/02/2025

GLP-1-S<br>11.45mg<br>Batch V250915-17 003<br>10/02/2025

GLP-1-S
11.45mg
Batch V250915-17 003
10/02/2025

GLP-1-S<br>10.10mg<br>Batch V250606-26 004<br>06/20/2025

GLP-1-S
10.10mg
Batch V250606-26 004
06/20/2025

Older GMP Certificates of Analysis

GLP-1-S 5.19mg Batch V250606-26 003 06/20/2025

GLP-1-S 10.2mg Batch #PKSEM1011525 01/15/2025

GLP-1-S 10.3mg Batch PKSEM10121024 12/10/24

GLP-1-S 5.2mg Batch PKSEM05121024 12/10/24

GLP-1-S 10.5mg Batch PKSEM10924 9/10/24

GLP-1-S 5mg Batch PKSEM05924 9/10/24

Research Certificates of Analysis

GLP-1-S<br>11.92mg<br>Batch V250915-17 001<br>10/02/2025

GLP-1-S
11.92mg
Batch V250915-17 001
10/02/2025

GLP-1-S<br>5.98mg<br>Batch V250826-9 002<br>09/12/2025

GLP-1-S
5.98mg
Batch V250826-9 002
09/12/2025

GLP-1-S<br>12.13mg<br>Batch V250826-9 001<br>09/12/2025

GLP-1-S
12.13mg
Batch V250826-9 001
09/12/2025

GLP-1-S<br>5.66mg<br>Task #42243<br>Batch #05172024<br>05/17/2024

GLP-1-S
5.66mg
Task #42243
Batch #05172024
05/17/2024

GLP-1-S<br>12.07mg<br>Task #42392<br>Batch #04302024<br>05/08/2024

GLP-1-S
12.07mg
Task #42392
Batch #04302024
05/08/2024

Older Research Certificates of Analysis

GLP-1-S 10.49mg Batch 04102024 4/16/24

GLP-1-S 10.27mg Batch 04082024 4/12/24

GLP-1-S Peptide Structure

Source: PubChem

PubChem Identifier: CID 56843331

Sequence: HXEGTFTSDVSSYLEGQAAK-OH.steric diacid-EFIAWLVRGRG

Molecular Formula: C187H291N45O59

Molecular Weight: 4113.64 g/mol

CAS Number: 910463-68-2

Synonyms: Semaglutide, Oxempic, Rybelsus, NN9535

Order GLP-1-S 5mg

Order GLP-1-S 10mg

Order GMP GLP-1-S 5mg

Order GMP GLP-1-S 10mg

Product Usage

This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.

Order GLP-1-S 5mg

Order GLP-1-S 10mg

Order GMP GLP-1-S 5mg

Order GMP GLP-1-S 10mg